![Pfizer's RSV vaccine enters late-stage trial, company says](https://static.foxnews.com/foxnews.com/content/uploads/2019/03/iStock-Lab.jpg)
Pfizer's RSV vaccine enters late-stage trial, company says
Fox News
Pharmaceutical company Pfizer announced on Thursday that its vaccine for the respiratory syncytial virus, or RSV, has begun the third phase of its clinical trials among adults, which comes almost two weeks after the Food Drug Administration (FDA) has fully authorized Pfizer's SARS-CoV-2 or COVID-19 vaccine.
RSV, commonly mistaken for COVID-19 due to similarities in symptoms, is a common respiratory virus. According to the CDC, most children likely had an RSV infection by the age of 2. While most adults recover within one to two weeks, RSV can be dangerous for infants and the elderly. For children younger than 1 year, RSV is the most common cause of bronchiolitis and pneumonia. Symptoms of RSV usually come in stages and can include, but are not limited to: runny nose, decrease in appetite, coughing, sneezing, fever and wheezing.More Related News